CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis

Inclusion Criteria:

• Male and female patients aged 12 - 70 years.

• Who was diagnosed with Atopic Dermatitis according to Haniffin and Rajka criteria.

• Whose affected TBSA is over 5% and below 30%, and IGA score is 2 (mild) to 3 (moderate).

• Who voluntarily agreed to participate in the study and signed an informed consentform.

Exclusion Criteria:

• Who has skin diseases other than atopic dermatitis or scar in the affected area whichcan affect the study, determined by the study investigators.

• Who has clinically significant medical history or diseases involving liver, kidney,neurological system, psychical disorder that can affect study results.

• Who has used systemic steroids, antibiotics, immunosuppressants, or receivedphototherapy within 28 days before study drug administration.

• Who has used topical steroids, topical calcineurin inhibitors or antibiotics to treatatopic dermatitis within 14 days before study drug administration.

• Who has used or is expected to inevitably use prohibited concomitant medicationsduring the study.

• Women who is pregnant /breast-feeding, or who has childbearing potential and does notuse available contraceptives.

• Who has dosed other study medications within 30 days before screening.

• Who is determined ineligible for study participation by investigators for any otherreasons.